Scrip
29 May 2009
Katie McQue
The US FDA has issued a complete response letter to Johnson & Johnson and Bayer for their oral, once-daily anticoagulant Xarelto (rivaroxaban).
The companies have not disclosed the contents of the letter but said the agency did not request any new clinical or non-clinical studies....
Please Login to read the full article.
RELATED CONTENT
NEWS
- GlaxoSmithKline's Votrient gets US panel nod for renal cancer
- Bayer/J&J plan a complete response to the FDA on anticoagulant Xarelto
- Daiichi Sankyo's edoxaban enters pivotal trial for VTE
- Xarelto stumbles on filing update but shines in long-term treatment for VTE risk reduction
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
